Crowley P
Department of Obstetrics and Gynaecology, Trinity College Dublin, Coombe Womens Hospital, Dublin 8, Ireland.
Cochrane Database Syst Rev. 2000(2):CD000065. doi: 10.1002/14651858.CD000065.
Respiratory distress syndrome is a serious complication of prematurity causing significant immediate and long-term mortality and morbidity.
The objective of this review was to assess the effects of corticosteroids administered to pregnant women to accelerate fetal lung maturity prior to preterm delivery.
The Cochrane Pregnancy and Childbirth Group trials register was searched.
Randomised and quasi-randomised trials of corticosteroid drugs capable of crossing the placenta compared with placebo or no treatment in women expected to deliver preterm as a result of either spontaneous preterm labour, prelabour rupture of the membranes preterm, or elective preterm delivery.
Eligibility and trial quality were assessed by one reviewer.
Eighteen trials including data on over 3700 babies were included. Antenatal administration of 24 milligrams of betamethasone, of 24 milligrams of dexamethasone, or two grams of hydrocortisone to women expected to give birth preterm was associated with a significant reduction in mortality (odds ratio 0.60, 95% confidence interval 0.48 to 0.75), respiratory distress syndrome (odds ratio 0.53, 95% confidence interval 0.44 to 0.63) and intraventricular haemorrhage in preterm infants. These benefits extended to a broad range of gestational ages and were not limited by gender or race. No adverse consequences of prophylactic corticosteroids for preterm birth have been identified.
REVIEWER'S CONCLUSIONS: Corticosteroids given prior to preterm birth (as a result of either preterm labour or elective preterm delivery) are effective in preventing respiratory distress syndrome and neonatal mortality. However there is not enough evidence to evaluate the use of repeated doses of corticosteroids in women who remain undelivered, but who are at continued risk of preterm birth. (This abstract has been prepared centrally.)
呼吸窘迫综合征是早产的一种严重并发症,会导致显著的近期和长期死亡率及发病率。
本综述的目的是评估给孕妇使用皮质类固醇以在早产前加速胎儿肺成熟的效果。
检索了Cochrane妊娠与分娩组试验注册库。
将能够穿过胎盘的皮质类固醇药物与安慰剂或未治疗进行比较的随机和半随机试验,受试女性因自发性早产、胎膜早破早产或选择性早产而预期会早产。
由一名综述作者评估入选资格和试验质量。
纳入了18项试验,涉及超过3700名婴儿的数据。对预期早产的女性产前给予24毫克倍他米松、24毫克地塞米松或2克氢化可的松,与死亡率(比值比0.60,95%置信区间0.48至0.75)、呼吸窘迫综合征(比值比0.53,95%置信区间0.44至0.63)及早产儿脑室内出血的显著降低相关。这些益处扩展至广泛的孕周范围,且不受性别或种族限制。未发现预防性使用皮质类固醇对早产有不良后果。
早产前(因早产或选择性早产)给予皮质类固醇可有效预防呼吸窘迫综合征和新生儿死亡。然而,没有足够证据评估对仍未分娩但仍有早产风险的女性重复使用皮质类固醇的情况。(本摘要由中心统一编写。)